Menu
October 16, 2023 : EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the US and Canada, today announced that it will present 28 abstracts featuring the latest research on the company’s oncology portfolio addressing unmet needs across bladder, head and neck, lung, colorectal and other cancers at the European Society for Medical Oncology (ESMO) Congress 2023, which will be held virtually and in-person in Madrid, Spain from October 20 to 24.
EMD Serono is committed to developing innovative cancer treatments that improve patients’ lives. The company’s oncology portfolio includes a number of promising new therapies that are currently in clinical development.
Some of the key highlights of the company’s presentation at ESMO 2023 include the following:
Bladder cancer: EMD Serono will present data from a Phase 3 trial of its investigational drug, pembrolizumab, in combination with chemotherapy for patients with advanced bladder cancer. The data showed that the combination treatment significantly improved overall and progression-free survival compared to chemotherapy alone.
Head and neck cancer: EMD Serono will present data from a Phase 3 trial of its investigational drug, tislelizumab, in combination with chemotherapy for patients with first-line recurrent or metastatic head and neck squamous cell carcinoma. The data showed that the combination treatment significantly improved overall and progression-free survival compared to chemotherapy alone.
Non-small cell lung cancer (NSCLC): EMD Serono will present data from a Phase 3 trial of its investigational drug, dostarlimab, in combination with chemotherapy for patients with advanced NSCLC. The data showed that the combination treatment significantly improved overall and progression-free survival compared to chemotherapy alone.
Colorectal cancer: EMD Serono will present data from a Phase 3 trial of its investigational drug, cetuximab, in combination with chemotherapy for patients with advanced colorectal cancer. The data showed that the combination treatment significantly improved overall and progression-free survival compared to chemotherapy alone.
EMD Serono’s presentation at ESMO 2023 will highlight the company’s commitment to developing innovative cancer treatments that improve patients’ lives. The company’s oncology portfolio includes several promising new therapies currently in clinical development, and the company is hopeful that these therapies will eventually make a significant difference in the lives of cancer patients around the world.
